Clairity, Inc.

Name: Clairity, Inc.
Brand: Clairity, Inc.

AI Native

Fulfilling the promise of precision medicine through the power of AI

Est 2020|Valuation $137M|Raised $53.8M|2 Ref Customers

LinkedIn 3K|Web traffic 3K|FTEs 15|HQ Boston, Massachusetts, US

01Competitive Landscape

Narrative analysis

Clairity vs iCAD: iCAD positions ProFound AI Risk around a shorter-horizon risk prediction and a broader breast health suite; Clairity’s stated differentiation is a multi-year risk prediction based on screening mammography alone.
Clairity vs workflow-first risk platforms: Tools like MagView Luminary Risk operationalize standard models across a population, but those models often require structured clinical inputs. Clairity aims to provide an image-derived signal without additional questionnaires (though implementation still requires governance).
Market adoption trend: Risk-based screening is a growing theme in breast imaging, but the segment is still forming. Clairity’s De Novo authorization provides regulatory context, but payer coverage and guideline incorporation will heavily influence adoption speed.

- Clairity vs iCAD: iCAD positions ProFound AI Risk around a shorter-horizon risk prediction and a broader breast health suite; Clairity’s stated differentiation is a multi-year risk prediction based on screening mammography alone. - Clairity vs workflow-first risk platforms: Tools like MagView Luminary Risk operationalize standard models across a population, but those models often require structured clinical inputs. Clairity aims to provide an image-derived signal without additional questionnaires (though implementation still requires governance). - Market adoption trend: Risk-based screening is a growing theme in breast imaging, but the segment is still forming. Clairity’s De Novo authorization provides regulatory context, but payer coverage and guideline incorporation will heavily influence adoption speed.

	Clairity Breast (Clairity)	iCAD ProFound AI Risk	MagView Luminary Risk + traditional models
Starting Price	Not public (enterprise quote)	Not public (enterprise quote)	Not public (enterprise quote)
Best For	Imaging centers seeking an FDA-authorized multi-year image-only risk score from screening mammograms	Sites already using iCAD suite; interest in shorter-horizon risk prediction and integration with detection tools	Programs focused on risk workflow and established clinical models (Tyrer-Cuzick/Gail/BRCAPro) and operational tracking
Key Strength	Multi-year risk horizon derived from mammography; De Novo authorization for this class	Established vendor in breast imaging AI; broader detection/risk suite positioning	Operational and workflow tooling; integrates multiple standard risk calculators
Key Weakness	Limited public evidence on real-world outcomes and pricing; early commercialization; reimbursement uncertain	Risk horizon and methodology differ; may be less aligned with longer-term preventive planning	Risk accuracy depends on data completeness and clinical input availability

Clairity, Inc.

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map